You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 6 (2016)

The issue number is given in front of the pagination

Aarsland, D., see Hessen, E. (2) 413-421

Aarsland, D., see Lee, J.H. (4) 733-739

Adler, C.H., see Beach, T.G. (1) 153-163

Adler, C.H., see Beach, T.G. (4) 761-770

Aerts, M.B., see Molenaar, J.P. (1) 53-55

Agosti, V., see Sorrentino, P. (1) 191-195

Ahmad, R., see Hossein-nezhad, A. (1) 109-117

Ahn, J., see Pagan, F. (3) 503-517

Akaike, A., see Izumi, Y. (3) 569-579

Alken, A.G., see Sidtis, J.J. (2) 361-370

Almendra, L., see Araújo, R. (4) 717-721

Alterman, R., see Sidtis, J.J. (2) 361-370

Alvariza, A., see Olsson, Y. (3) 581-587

Alzahrani, H., A. Antonini and A. Venneri, Apathy in Mild Parkinson’s Disease: Neuropsychological and Neuroimaging Evidence (4) 821-832

Antonini, A., see Alzahrani, H. (4) 821-832

Aparasu, R.R., see Chekani, F. (3) 617-624

Arai, T., see Hatsuta, H. (2) 325-334

Araújo, R., M. Tábuas-Pereira, L. Almendra, J. Ribeiro, M. Arenga, L. Negrão, A. Matos, A. Morgadinho and C. Januário, Tremor Frequency Assessment by iPhone® Applications: Correlation with EMG Analysis (4) 717-721

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016? (1) 57-63

Arenga, M., see Araújo, R. (4) 717-721

Ares, B., see Fernández-Pajarín, G. (4) 787-792

Årestedt, K., see Olsson, Y. (3) 581-587

Arizona Parkinson’s Disease Consortium see Beach, T.G. (1) 153-163

Asgharnejad, M., see Giladi, N. (2) 401-411

Asgharnejad, M., see Giladi, N. (4) 741-749

Atkinson, R.A., see Barnish, J. (3) 473-484

Atsuta, N., see Tanaka, Y. (4) 811-819

Auning, E., see Hessen, E. (2) 413-421

Baille, G., A.M. De Jesus, T. Perez, D. Devos, K. Dujardin, C.M. Charley, L. Defebvre and C. Moreau, Ventilatory Dysfunction in Parkinson’s Disease (3) 463-471

Bajaj, N.P., see Swallow, D.M.A. (2) 289-300

Bali, V., see Chekani, F. (3) 617-624

Ballanger, B., see Criaud, M. (2) 433-440

Ballard, C.G., see Lee, J.H. (4) 733-739

Baraduc, P., see Criaud, M. (2) 433-440

Barbato, A., see Sorrentino, P. (1) 191-195

Barker, R.A., M. Parmar, A. Kirkeby, A. Björklund, L. Thompson and P. Brundin

Barker, R.A., see Swallow, D.M.A. (2) 289-300

Barnish M.S., see Barnish, J. (3) 473-484

Barnish, J., R.A. Atkinson, S.M. Barran and M.S. Barnish, Potential Benefit of Singing for People with Parkinson’s Disease: A Systematic Review (3) 473-484

Barnish, M.S., D. Whibley, S.M.C. Horton, Z.R. Butterfint and K.H.O. Deane, Roles of Cognitive Status and Intelligibility in Everyday Communication in People with Parkinson’s Disease: A Systematic Review (3) 453-462

Barran, S.M., see Barnish, J. (3) 473-484

Barrett, M.J., A.F. Koeppel, J.L. Flanigan, S.D. Turner and B.B. Worrall, Investigation of Genetic Variants Associated with Alzheimer Disease in Parkinson Disease Cognition (1) 119-124

Barthel, C., E. Mallia, B. Debû, B.R. Bloem and M.U. Ferraye, The Practicalities of Assessing Freezing of Gait (4) 667-674

Bauer, L., see Giladi, N. (2) 401-411

Bauer, L., see Giladi, N. (4) 741-749

Beach, T.G., A.-G. Corbille, F. Letournel, J.H. Kordower, T. Kremer, D.G. Munoz, A. Intorcia, J. Hentz, C.H. Adler, L.I. Sue, J. Walker, G. Serrano and P. Derkinderen, Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson’s Disease and Control Subjects (4) 761-770

Beach, T.G., C.H. Adler, G. Serrano, L.I. Sue, D.G. Walker, B.N. Dugger, H.A. Shill, E. Driver-Dunckley, J.N. Caviness, A. Intorcia, J. Filon, S. Scott, A. Garcia, B. Hoffman, C.M. Belden, K.J. Davis, M.N. Sabbagh and the Arizona Parkinson’s Disease Consortium, Prevalence of Submandibular Gland Synucleinopathy in Parkinson’s Disease, Dementia with Lewy Bodies and other Lewy Body Disorders (1) 153-163

Belden, C.M., see Beach, T.G. (1) 153-163

Ben-Shlomo, Y., see Swallow, D.M.A. (2) 289-300

Berendse, H.W., see Rimmelzwaan, L.M. (1) 29-37

Bhattacharjee, S., L. Goldstone and T. Warholak, Prevalence, Patterns and Predictors of Psychotropic Polypharmacy Among Elderly Individuals with Parkinson’s Disease In Long Term Care Settings In The United States (1) 247-255

Bichon, A., see Lamberti, V.M.J. (1) 133-142

Bichon, A., see Rieu, I. (1) 267-277

Björklund, A., see Barker, R.A. (1) 57-63

Blake, C., see Kelly, B. (4) 709-716

Bloem, B.R., see Barthel, C. (4) 667-674

Bloem, B.R., see Hommel, A.L.A.J. (4) 805-810

Bloem, B.R., see Molenaar, J.P. (1) 53-55

Bloem, B.R., see Nijhuis, F.A.P. (3) 533-543

Blomsø, L., see Hessen, E. (2) 413-421

Böckmann, A., see Bousset, L. (1) 143-151

Boman, A., S. Svensson, A. Boxer, J.C. Rojas, W.W. Seeley, A. Karydas, B. Miller, K. Kågedal and P. Svenningsson, Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid (2) 307-315

Bonizzoni E., see Cattaneo, C. (1) 165-173

Booth, L., see Johnson, A.R. (3) 609-616

Bordelon, Y., see Paul, K.C. (2) 349-359

Boroojerdi, B., see Giladi, N. (2) 401-411

Boulinguez, P., see Criaud, M. (2) 433-440

Bourriez, J.-L., see Carriere, N. (3) 651-666

Bousset, L., P. Brundin, A. Böckmann, B. Meier and R. Melki, An Efficient Procedure for Removal and Inactivation of Alpha-Synuclein Assemblies from Laboratory Materials (1) 143-151

Bouwyn, J.-P., S. Derrey, R. Lefaucheur, D. Fetter, A. Rouille, F. Le Goff and D. Maltête, Age Limits for Deep Brain Stimulation of Subthalamic Nuclei in Parkinson’s Disease (2) 393-400

Boxer, A., see Boman, A. (2) 307-315

Brady, S.T., see Kurowska, Z. (4) 703-707

Braybrook, M., S. O’Connor, P. Churchward, T. Perera, P. Farzanehfar and M. Horne, An Ambulatory Tremor Score for Parkinson’s Disease (4) 723-731

Brefel-Courbon, C., see Rieu, I. (1) 267-277

Bresolin, E., see van Uem, J.M.T. (2) 279-287

Bronstein, J.M., see Paul, K.C. (2) 349-359

Broussolle, E., see Criaud, M. (2) 433-440

Brundin, P., see Barker, R.A. (1) 57-63

Brundin, P., see Bousset, L. (1) 143-151

Brundin, P., see Kurowska, Z. (4) 703-707

Brundin, P., see Wyse, R.K. (3) 519-522

Bucks, R.S., see Johnson, A.R. (3) 609-616

Burke, R.E., see Kurowska, Z. (4) 703-707

Burke, R.E., see Tagliaferro, P. (1) 1-5

Burn, D.J., see Swallow, D.M.A. (2) 289-300

Butterfint, Z.R., see Barnish, M.S. (3) 453-462

Byrne, D.W., see Hacker, M.L. (1) 125-131

Cai, Q.-Q., see Wang, Z.-Y. (2) 317-323

Calejo, M., see Mendes, A. (4) 793-804

Canesi, M., M.L. Rusconi, F. Moroni, A. Ranghetti, E. Cereda and G. Pezzoli, Creative Thinking, Professional Artists, and Parkinson’s Disease (1) 239-246

Carlson, A., see Pagan, F. (3) 503-517

Carriere, N., J.-L. Bourriez, A. Delval, P. Derambure, L. Defebvre and K. Dujardin, Impulse Control Disorders in Parkinson’s Disease are Associated with Alterations in Reward-Related Cortical Oscillations (3) 651-666

Castrioto, A., see Lamberti, V.M.J. (1) 133-142

Castro, A., see Fernández-Pajarín, G. (4) 787-792

Cattaneo, C., M. Sardina and E. Bonizzoni, Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE (1) 165-173

Cavaco, S., see Mendes, A. (4) 793-804

Cavanaugh, J.T., see Paul, S.S. (2) 301-305

Caviness, J.N., see Beach, T.G. (1) 153-163

Cereda, E., see Canesi, M. (1) 239-246

Cervantes-Arriaga, A., see Rodríguez-Violante, M. (1) 183-190

Charles, D., see Hacker, M.L. (1) 125-131

Charley, C.M., see Baille, G. (3) 463-471

Chekani, F., V. Bali and R.R. Aparasu, Functional Status of Elderly Nursing Home Residents With Parkinson’s Disease (3) 617-624

Chen, C.P., see Lee, J.H. (4) 733-739

Chéreau, I., see Rieu, I. (1) 267-277

Cherif, M., see Jacobs, M.L. (1) 231-237

Cheung, V., see Mak, M.K.Y. (3) 639-650

Chodosh, J., see Fleisher, J.E. (2) 383-392

Choi, J.H., see Oh, Y.-S. (4) 771-778

Chu, W.C.W., see Mak, M.K.Y. (3) 639-650

Chu, Y., G.A. Morfini and J.H. Kordower, Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson’s Disease (1) 77-97

Chung, S.J., see Kim, H.J. (4) 675-683

Churchward, P., see Braybrook, M. (4) 723-731

Ciucci, M.R., see Jones, C.A. (1) 197-208

Claassen, D.O., see Herb, J.N. (2) 441-451

Clarén, L., see Olsson, Y. (3) 581-587

Conradsson, D., see Nero, H. (4) 833-840

Corbille, A.-G., see Beach, T.G. (4) 761-770

Corti, E.J., see Johnson, A.R. (3) 609-616

Creek, M.M., see Paul, K.C. (2) 349-359

Criaud, M., A. Poisson, S. Thobois, E. Metereau, J. Redouté, D. Ibarrola, P. Baraduc, E. Broussolle, A.P. Strafella, B. Ballanger and P. Boulinguez, Slowness in Movement Initiation is Associated with Proactive Inhibitory Network Dysfunction in Parkinson’s Disease (2) 433-440

Cubo, E., see Heldman, D.A. (3) 631-638

Currie, A.D., see Hacker, M.L. (1) 125-131

Dahodwala, N.A., see Fleisher, J.E. (2) 383-392

Damásio, J., see Mendes, A. (4) 793-804

Daneault, J.-F., see Lauzé, M. (4) 685-698

Dauvilliers, Y., see Jacobs, M.L. (1) 231-237

Davis, K.J., see Beach, T.G. (1) 153-163

Davis, T.L., see Hacker, M.L. (1) 125-131

Dawant, B.M., see Herb, J.N. (2) 441-451

De Bodt, M., see Martens, H. (1) 219-229

De Chazeron, I., see Rieu, I. (1) 267-277

De Jesus, A.M., see Baille, G. (3) 463-471

de Saráchaga, A.J., see Rodríguez-Violante, M. (1) 183-190

Deane K.H.O., see Barnish, M.S. (3) 453-462

Debû, B., see Barthel, C. (4) 667-674

Defebvre, L., see Baille, G. (3) 463-471

Defebvre, L., see Carriere, N. (3) 651-666

Delval, A., see Carriere, N. (3) 651-666

Derambure, P., see Carriere, N. (3) 651-666

Derkinderen, P., see Beach, T.G. (4) 761-770

Derrey, S., see Bouwyn, J.-P. (2) 393-400

Deuschl, G., see Margraf, N.G. (3) 485-501

Devos, D., see Baille, G. (3) 463-471

Dibble, L.E., see Paul, S.S. (2) 301-305

Dohin, E., see Giladi, N. (4) 741-749

Donahue, M.J., see Herb, J.N. (2) 441-451

Driver-Dunckley, E., see Beach, T.G. (1) 153-163

Du, G., see He, L. (3) 523-532

Du, G., see Sterling, N.W. (3) 557-567

Dugger, B.N., see Beach, T.G. (1) 153-163

Dujardin, K., see Baille, G. (3) 463-471

Dujardin, K., see Carriere, N. (3) 651-666

Dujardin, K., see Rieu, I. (1) 267-277

Dunn, C., see Pagan, F. (3) 503-517

Durif, F., see Lamberti, V.M.J. (1) 133-142

Durif, F., see Rieu, I. (1) 267-277

Duval, C., see Lauzé, M. (4) 685-698

Earhart, G.M., see Paul, S.S. (2) 301-305

Ebersbach, G., see Ossig, C. (3) 597-607

Eekhoff, E.M.W., see Rimmelzwaan, L.M. (1) 29-37

Eliassen, C.F., see Hessen, E. (2) 413-421

Ellis, T.D., see Paul, S.S. (2) 301-305

Eslinger, P.J., see He, L. (3) 523-532

Espay, A.J., see van Uem, J.M.T. (2) 279-287

Esselink, R.A., see Molenaar, J.P. (1) 53-55

Esselink, R.A.J., see Lamberti, V.M.J. (1) 133-142

Estrada-Bellmann, I., see Rodríguez-Violante, M. (1) 183-190

Evans, A., see Lee, W. (2) 371-382

Faber, M.J., see Hommel, A.L.A.J. (4) 805-810

Faber, M.J., see Nijhuis, F.A.P. (3) 533-543

Faghihi, M.A., see Hossein-nezhad, A. (1) 109-117

Falconer, R.A., see Pagan, F. (3) 503-517

Farzanehfar, P., see Braybrook, M. (4) 723-731

Fatemi, R.P., see Hossein-nezhad, A. (1) 109-117

Fauser, M., see Ossig, C. (3) 597-607

Fernandes, J., see Mendes, A. (4) 793-804

Fernández-Pajarín, G., Á. Sesar, B. Ares and A. Castro, Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson’s Disease: The APO-NIGHT Study (4) 787-792

Ferraye, M.U., see Barthel, C. (4) 667-674

Fetter, D., see Bouwyn, J.-P. (2) 393-400

Fetter, D., see Rabel, C. (4) 779-785

Filon, J., see Beach, T.G. (1) 153-163

Fladby, T., see Hessen, E. (2) 413-421

Flanigan, J.L., see Barrett, M.J. (1) 119-124

Fleisher, J.E., N.A. Dahodwala, S.X. Xie, M. Mayo, D. Weintraub, J. Chodosh and J.A. Shea, Development and Validation of the Parkinson’s Disease Medication Beliefs Scale (PD-Rx) (2) 383-392

Foltynie, T., see Swallow, D.M.A. (2) 289-300

Ford, M.P., see Paul, S.S. (2) 301-305

Foreman, K.B., see Paul, S.S. (2) 301-305

Fraix, V., see Lamberti, V.M.J. (1) 133-142

Francis, P.T., see Lee, J.H. (4) 733-739

Franzén, E., see Nero, H. (4) 833-840

Fujimoto, Y., see Tanaka, Y. (4) 811-819

Futamura, A., see Murakami, H. (1) 209-217

Gagnon, J.-F., see Jacobs, M.L. (1) 231-237

Gandor, F., see Ossig, C. (3) 597-607

Garcia, A., see Beach, T.G. (1) 153-163

Gasser, T., Personalized Medicine Approaches in Parkinson’s Disease: The Genetic Perspective (4) 699-701

Gasson, N., see Johnson, A.R. (3) 609-616

Gaudio, L.D., see Sorrentino, P. (1) 191-195

Giladi, N., A.P. Nicholas, M. Asgharnejad, E. Dohin, F. Woltering, L. Bauer and W. Poewe, Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage (4) 741-749

Giladi, N., M. Asgharnejad, L. Bauer, F. Grieger and B. Boroojerdi, Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis (2) 401-411

Gilat, M., see Szeto, J.Y.Y. (3) 589-596

Giuffrida, J.P., see Heldman, D.A. (3) 631-638

Godfrey, A., see Hiorth, Y.H. (1) 175-182

Goff, F.L., see Rabel, C. (4) 779-785

Goldstone, L., see Bhattacharjee, S. (1) 247-255

Gonçalves, A., see Mendes, A. (4) 793-804

Grieger, F., see Giladi, N. (2) 401-411

Grosset, D.G., on behalf of PRoBaND Clinical Consortium, see Swallow, D.M.A. (2) 289-300

Grosset, K.A., see Swallow, D.M.A. (2) 289-300

Gu, Q., H. Zhang, M. Xuan, W. Luo, P. Huang, S. Xia and M. Zhang, Automatic Classification on Multi-Modal MRI Data for Diagnosis of the Postural Instability and Gait Difficulty Subtype of Parkinson’s Disease (3) 545-556

Gunnery, S.D., B. Habermann, M. Saint-Hilaire, C.A. Thomas and L. Tickle-Degnen, The Relationship between the Experience of Hypomimia and Social Wellbeing in People with Parkinson’s Disease and their Care Partners (3) 625-630

Habermann, B., see Gunnery, S.D. (3) 625-630

Hacker, M.L., A.D. Currie, A.L. Molinari, M. Turchan, S.M. Millan, L.E. Heusinkveld, J. Roach, P.E. Konrad, T.L. Davis, J.S. Neimat, F.T. Phibbs, P. Hedera, D.W. Byrne and D. Charles, Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson’s Disease (1) 125-131

Hagell, P., see Olsson, Y. (3) 581-587

Hagströmer, M., see Nero, H. (4) 833-840

Hallett, M., see Mak, M.K.Y. (3) 639-650

Hamberg, K., see Hariz, G.-M. (2) 335-347

Hansson, O., see Lindqvist, D. (1) 99-108

Hardy, J., see Swallow, D.M.A. (2) 289-300

Hariz, G.-M., P. Limousin and K. Hamberg, “DBS means everything – for some time”. Patients’ Perspectives on Daily Life with Deep Brain Stimulation for Parkinson’s Disease (2) 335-347

Hatsuta, H., M. Takao, Y. Nakano, A. Nogami, A. Uchino, H. Sumikura, K. Kanemaru, T. Arai, Y. Itoh and S. Murayama, Reduction of Small Fibers of Thoracic Ventral Roots and Neurons of Intermediolateral Nucleus in Parkinson Disease and Dementia with Lewy Bodies (2) 325-334

He, L., E.-Y. Lee, N.W. Sterling, L. Kong, M.M. Lewis, G. Du, P.J. Eslinger and X. Huang, The Key Determinants to Quality of Life in Parkinson’s Disease Patients: Results from the Parkinson’s Disease Biomarker Program (PDBP) (3) 523-532

Hebron, M., see Pagan, F. (3) 503-517

Hedera, P., see Hacker, M.L. (1) 125-131

Hedera, P., see Herb, J.N. (2) 441-451

Heldman, D.A., J.P. Giuffrida and E. Cubo, Wearable Sensors for Advanced Therapy Referral in Parkinson’s Disease (3) 631-638

Hentz, J., see Beach, T.G. (4) 761-770

Herb, J.N., S. Rane, D.A. Isaacs, N.V. Wouwe, O.C. Roman, B.A. Landman, B.M. Dawant, P. Hedera, D.H. Zald, J.S. Neimat, S.A. Wylie, M.J. Donahue and D.O. Claassen, Cortical Implications of Advancing Age and Disease Duration in Parkinson’s Disease Patients with Postural Instability and Gait Dysfunction (2) 441-451

Hessen, E., A.L. Stav, E. Auning, P. Selnes, L. Blomsø, C.E. Holmeide, K.K. Johansen, C.F. Eliassen, I. Reinvang, T. Fladby and D. Aarsland, Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s Diseases (2) 413-421

Heusinkveld, L.E., see Hacker, M.L. (1) 125-131

Hiorth, Y.H., J.P. Larsen, K. Lode, O.-B. Tysnes, A. Godfrey, S. Lord, L. Rochester and K.F. Pedersen, Impact of Falls on Physical Activity in People with Parkinson’s Disease (1) 175-182

Hirayama, M., M. Tsunoda, M. Yamamoto, T. Tsuda and K. Ohno, Serum Tyrosine-to-Phenylalanine Ratio is Low in Parkinson’s Disease (2) 423-431

Hoffman, B., see Beach, T.G. (1) 153-163

Holmeide, C.E., see Hessen, E. (2) 413-421

Hommel, A.L.A.J., M.J. Faber, N.J. Weerkamp, J.G. van Dijk, B.R. Bloem and R.T. Koopmans, Prevalence and Prescribed Treatments of Orthostatic Hypotension in Institutionalized Patients with Parkinson’s Disease (4) 805-810

Horne, M., see Braybrook, M. (4) 723-731

Horton,S.M.C., see Barnish, M.S. (3) 453-462

Hossein-nezhad, A., R.P. Fatemi, R. Ahmad, E.R. Peskind, C.P. Zabetian, S.-C. Hu, M. Shi, C. Wahlestedt, J. Zhang and M.A. Faghihi, Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson’s Disease (1) 109-117

Houeto, J.L., see Rieu, I. (1) 267-277

Howard, H., see Pagan, F. (3) 503-517

Hu, S.-C., see Hossein-nezhad, A. (1) 109-117

Huang, P., see Gu, Q. (3) 545-556

Huang, X., see He, L. (3) 523-532

Huang, X., see Pagan, F. (3) 503-517

Huang, X., see Sterling, N.W. (3) 557-567

Ibarrola, D., see Criaud, M. (2) 433-440

Intorcia, A., see Beach, T.G. (1) 153-163

Intorcia, A., see Beach, T.G. (4) 761-770

Isaacs, D.A., see Herb, J.N. (2) 441-451

Isaacs, T., see van Uem, J.M.T. (2) 279-287

Isaacson, S., H.A. Shill, S. Vernino, A. Ziemann and G.J. Rowse, Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303) (4) 751-759

Ishigaki, S., see Murakami, H. (1) 209-217

Ito, M., see Tanaka, Y. (4) 811-819

Itoh, Y., see Hatsuta, H. (2) 325-334

Izumi, Y., N. Kondo, R. Takahashi, A. Akaike and T. Kume, Reduction of Immunoreactivity Against the C-Terminal Region of the Intracellular α-Synuclein by Exogenous α-Synuclein Aggregates: Possibility of Conformational Changes (3) 569-579

Jacobs, M.L., Y. Dauvilliers, E.K. St. Louis, S.J. McCarter, S.R. Romenets, A. Pelletier, M. Cherif, J.-F. Gagnon and R.B. Postuma, Risk Factor Profile in Parkinson’s Disease Subtype with REM Sleep Behavior Disorder (1) 231-237

Janszky, J., see Weintraut, R. (1) 257-265

Januário, C., see Araújo, R. (4) 717-721

Jenner, P., see Stamford, J. (1) 65-66

Jeon, B., see Kim, H.J. (4) 675-683

Johansen, K.K., see Hessen, E. (2) 413-421

Johnson, A.R., B.J. Lawrence, E.J. Corti, L. Booth, N. Gasson, M.G. Thomas, A.M. Loftus and R.S. Bucks, Suitability of the Depression, Anxiety, and Stress Scale in Parkinson’s Disease (3) 609-616

Jones, C.A. and M.R. Ciucci, Multimodal Swallowing Evaluation with High-Resolution Manometry Reveals Subtle Swallowing Changes in Early and Mid-Stage Parkinson Disease (1) 197-208

Jost, W.H., see Ossig, C. (3) 597-607

Kågedal, K., see Boman, A. (2) 307-315

Kajita, Y., see Tanaka, Y. (4) 811-819

Kalaria, R.N., see Lee, J.H. (4) 733-739

Kanemaru, K., see Hatsuta, H. (2) 325-334

Karádi, K., see Weintraut, R. (1) 257-265

Karydas, A., see Boman, A. (2) 307-315

Katoh, H., see Murakami, H. (1) 209-217

Katsuno, M., see Tanaka, Y. (4) 811-819

Kawamura, M., see Murakami, H. (1) 209-217

Kelly, B., C. Blake and O. Lennon, Acute Hospital Admissions of Individuals with a Known Parkinson’s Disease Diagnosis in Ireland 2009–2012: A Short Report (4) 709-716

Kezuka, M., see Murakami, H. (1) 209-217

Kim, H.J., B. Jeon and S.J. Chung, Professional ethics in complementary and alternative medicines in management of Parkinson’s disease (4) 675-683

Kirkeby, A., see Barker, R.A. (1) 57-63

Kistner, A., see Lamberti, V.M.J. (1) 133-142

Koeppel, A.F., see Barrett, M.J. (1) 119-124

Kondo, N., see Izumi, Y. (3) 569-579

Kong, L., see He, L. (3) 523-532

Konrad, P.E., see Hacker, M.L. (1) 125-131

Koopmans, R.T., see Hommel, A.L.A.J. (4) 805-810

Kordower, J.H., see Beach, T.G. (4) 761-770

Kordower, J.H., see Chu, Y. (1) 77-97

Kordower, J.H., see Kurowska, Z. (4) 703-707

Kovács, M., see Weintraut, R. (1) 257-265

Kovács, N., see Weintraut, R. (1) 257-265

Krack, P., see Lamberti, V.M.J. (1) 133-142

Krack, P., see Mendes, A. (4) 793-804

Krack, P., see Rieu, I. (1) 267-277

Kremer, T., see Beach, T.G. (4) 761-770

Kume, T., see Izumi, Y. (3) 569-579

Kurowska, Z., J.H. Kordower, A.J. Stoessl, R.E. Burke, P. Brundin, Z. Yue, S.T. Brady, J. Milbrandt, B.D. Trapp, T.B. Sherer and S. Medicetty, Is Axonal Degeneration a Key Early Event in Parkinson’s Disease? (4) 703-707

Kwon, D.-Y., see Oh, Y.-S. (4) 771-778

Lai, M.K.P., see Lee, J.H. (4) 733-739

Lamberti, V.M.J., B. Pereira, E. Lhommée, A. Bichon, E. Schmitt, P. Pelissier, A. Kistner, V. Fraix, A. Castrioto, R.A.J. Esselink, F. Durif and P. Krack, Profile of Neuropsychiatric Symptoms in Parkinson’s Disease: Surgical Candidates Compared to Controls (1) 133-142

Landman, B.A., see Herb, J.N. (2) 441-451

Larsen, J.P., see Hiorth, Y.H. (1) 175-182

Lauzé, M., J.-F. Daneault and C. Duval, The Effects of Physical Activity in Parkinson’s Disease: A Review (4) 685-698

Lawler, A., see Pagan, F. (3) 503-517

Lawrence, B.J., see Johnson, A.R. (3) 609-616

Lawton, M.A., see Swallow, D.M.A. (2) 289-300

Le Goff, F., see Bouwyn, J.-P. (2) 393-400

Leal-Ortega, R., see Rodríguez-Violante, M. (1) 183-190

Lee, E.-Y., see He, L. (3) 523-532

Lee, J.H., P.T. Francis, C.G. Ballard, D. Aarsland, R.N. Kalaria, P.T.-H. Wong, C.P. Chen and M.K.P. Lai, Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson’s Disease Dementia (4) 733-739

Lee, W., A. Evans and D.R. Williams, Validation of a Smartphone Application Measuring Motor Function in Parkinson’s Disease (2) 371-382

Lefaucheur, R., see Bouwyn, J.-P. (2) 393-400

Lefaucheur, R., see Rabel, C. (4) 779-785

Leijten, Q.H., see Molenaar, J.P. (1) 53-55

Lennon, O., see Kelly, B. (4) 709-716

Letournel, F., see Beach, T.G. (4) 761-770

Lewin, A., see van Uem, J.M.T. (2) 279-287

Lewis, M.M., see He, L. (3) 523-532

Lewis, M.M., see Sterling, N.W. (3) 557-567

Lewis, S.J.G., see Szeto, J.Y.Y. (3) 589-596

Lhommée, E., see Lamberti, V.M.J. (1) 133-142

Li, Z., see Pagan, F. (3) 503-517

Lian, H., see Wang, Z.-Y. (2) 317-323

Lima, A.B., see Mendes, A. (4) 793-804

Limousin, P., see Hariz, G.-M. (2) 335-347

Lindqvist, D., I. Prokopenko, E. Londos, L. Middleton and O. Hansson, Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism (1) 99-108

Lips, P., see Rimmelzwaan, L.M. (1) 29-37

Lode, K., see Hiorth, Y.H. (1) 175-182

Loftus, A.M., see Johnson, A.R. (3) 609-616

Londos, E., see Lindqvist, D. (1) 99-108

Lord, S., see Hiorth, Y.H. (1) 175-182

Lou, W., see Mak, M.K.Y. (3) 639-650

Lu, Z.L., see Mak, M.K.Y. (3) 639-650

Lucza, T., see Weintraut, R. (1) 257-265

Luo, W., see Gu, Q. (3) 545-556

Ma, S., see Mak, M.K.Y. (3) 639-650

Maetzler, W., see van Uem, J.M.T. (2) 279-287

Mak, M.K.Y., V. Cheung, S. Ma, Z.L. Lu, D. Wang, W. Lou, L. Shi, V.C.T. Mok, W.C.W. Chu and M. Hallett, Increased Cognitive Control During Execution of Finger Tap Movement in People with Parkinson’s Disease (3) 639-650

Makkos, A., see Weintraut, R. (1) 257-265

Malek, N., see Swallow, D.M.A. (2) 289-300

Mallia, E., see Barthel, C. (4) 667-674

Maltête, D., see Bouwyn, J.-P. (2) 393-400

Maltête, D., see Rabel, C. (4) 779-785

Margraf, N.G., A. Wrede, G. Deuschl and W.J. Schulz-Schaeffer, Pathophysiological Concepts and Treatment of Camptocormia (3) 485-501

Martens, H., G.V. Nuffelen, K. Wouters and M. De Bodt, Reception of Communicative Functions of Prosody in Hypokinetic Dysarthria due to Parkinson’s Disease (1) 219-229

Martin, I., Decoding Parkinson’s Disease Pathogenesis: The Role of Deregulated mRNA Translation (1) 17-27

Matos, A., see Araújo, R. (4) 717-721

Matthews, H., see van Uem, J.M.T. (2) 279-287

Mayo, M., see Fleisher, J.E. (2) 383-392

McCarter, S.J., see Jacobs, M.L. (1) 231-237

Medicetty, S., see Kurowska, Z. (4) 703-707

Meier, B., see Bousset, L. (1) 143-151

Melki, R., see Bousset, L. (1) 143-151

Mendes, A., A. Gonçalves, N. Vila-Chã, M. Calejo, I. Moreira, J. Fernandes, J. Damásio, A. Teixeira-Pinto, P. Krack, A.B. Lima and S. Cavaco, Statistical Models of Parkinson’s Disease Progression: Predictive Validity in a 3-Year Follow-up (4) 793-804

Metereau, E., see Criaud, M. (2) 433-440

Middleton, L., see Lindqvist, D. (1) 99-108

Milbrandt, J., see Kurowska, Z. (4) 703-707

Millan, S.M., see Hacker, M.L. (1) 125-131

Millán-Cepeda, R., see Rodríguez-Violante, M. (1) 183-190

Miller, B., see Boman, A. (2) 307-315

Miller, M.W., see Murakami, H. (1) 209-217

Mills, R.R., see Pagan, F. (3) 503-517

Mok, V.C.T., see Mak, M.K.Y. (3) 639-650

Molenaar, J.P., J. Wilbers, M.B. Aerts, Q.H. Leijten, J.G. van Dijk, R.A. Esselink and B.R. Bloem, Sudden Death: An Uncommon Occurrence in Dementia with Lewy Bodies (1) 53-55

Molinari, A.L., see Hacker, M.L. (1) 125-131

Momma, Y., see Murakami, H. (1) 209-217

Moreau, C., see Baille, G. (3) 463-471

Moreira, I., see Mendes, A. (4) 793-804

Morfini, G.A., see Chu, Y. (1) 77-97

Morgadinho, A., see Araújo, R. (4) 717-721

Mori, Y., see Murakami, H. (1) 209-217

Moroni, F., see Canesi, M. (1) 239-246

Morris, H.R., see Swallow, D.M.A. (2) 289-300

Moussa, C., see Pagan, F. (3) 503-517

Mowszowski, L., see Szeto, J.Y.Y. (3) 589-596

Munoz, D.G., see Beach, T.G. (4) 761-770

Murakami, H., Y. Momma, T. Nohara, Y. Mori, A. Futamura, T. Sugita, S. Ishigaki, H. Katoh, M. Kezuka, K. Ono, M.W. Miller and M. Kawamura, Improvement in Language Function Correlates with Gait Improvement in Drug-naïve Parkinson’s Disease Patients Taking Dopaminergic Medication (1) 209-217

Murayama, S., see Hatsuta, H. (2) 325-334

Naismith, S.L., see Szeto, J.Y.Y. (3) 589-596

Nakano, Y., see Hatsuta, H. (2) 325-334

Nakatsubo, D., see Tanaka, Y. (4) 811-819

Negrão, L., see Araújo, R. (4) 717-721

Neimat, J.S., see Hacker, M.L. (1) 125-131

Neimat, J.S., see Herb, J.N. (2) 441-451

Nero, H., M.B. Wallén, E. Franzén, D. Conradsson, A. Ståhle and M. Hagströmer, Objectively Assessed Physical Activity and its Association with Balance, Physical Function and Dyskinesia in Parkinson’s Disease (4) 833-840

Nicholas, A.P., see Giladi, N. (4) 741-749

Nijhuis, F.A.P., J. van Heek, B.R. Bloem, B. Post and M.J. Faber, Choosing an Advanced Therapy in Parkinson’s Disease; is it an Evidence-Based Decision in Current Practice? (3) 533-543

Nogami, A., see Hatsuta, H. (2) 325-334

Nohara, T., see Murakami, H. (1) 209-217

Nuffelen, G.V., see Martens, H. (1) 219-229

O’Connor, S., see Braybrook, M. (4) 723-731

Oh, Y.-S., J.H. Choi and D.-Y. Kwon, Classification of Scans Without Evidence of Dopamine Deficit (SWEDD) According to the Olfactory Function (4) 771-778

Ohdake, R., see Tanaka, Y. (4) 811-819

Ohno, K., see Hirayama, M. (2) 423-431

Olsson, Y., L. Clarén, A. Alvariza, K. Årestedt and P. Hagell, Health and Social Service Access Among Family Caregivers of People with Parkinson’s Disease (3) 581-587

Ono, K., see Murakami, H. (1) 209-217

Ory-Magne, F., see Rieu, I. (1) 267-277

Ossig, C., D. Sippel, M. Fauser, F. Gandor, W.H. Jost, G. Ebersbach and A. Storch, Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson’s Disease (3) 597-607

Oueslati, A., Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? (1) 39-51

Ozel, G., see Rabel, C. (4) 779-785

Pagan, F., M. Hebron, E.H. Valadez, Y. Torres-Yaghi, X. Huang, R.R. Mills, B.M. Wilmarth, H. Howard, C. Dunn, A. Carlson, A. Lawler, S.L. Rogers, R.A. Falconer, J. Ahn, Z. Li and C. Moussa, Nilotinib Effects in Parkinson’s Disease and Dementia with Lewy Bodies (3) 503-517

Parmar, M., see Barker, R.A. (1) 57-63

Paul, K.C., R. Rausch, M.M. Creek, J.S. Sinsheimer, J.M. Bronstein, Y. Bordelon and B. Ritz, APOE, MAPT, and COMT and Parkinson’s Disease Susceptibility and Cognitive Symptom Progression (2) 349-359

Paul, S.S., T.D. Ellis, L.E. Dibble, G.M. Earhart, M.P. Ford, K.B. Foreman and J.T. Cavanaugh, Obtaining Reliable Estimates of Ambulatory Physical Activity in People with Parkinson’s Disease (2) 301-305

Pedersen, K.F., see Hiorth, Y.H. (1) 175-182

Pelissier, P., see Lamberti, V.M.J. (1) 133-142

Pelletier, A., see Jacobs, M.L. (1) 231-237

Pereira, B., see Lamberti, V.M.J. (1) 133-142

Pereira, B., see Rieu, I. (1) 267-277

Perera, T., see Braybrook, M. (4) 723-731

Perez, T., see Baille, G. (3) 463-471

Peskind, E.R., see Hossein-nezhad, A. (1) 109-117

Pezzoli G., see Canesi, M. (1) 239-246

Phibbs, F.T., see Hacker, M.L. (1) 125-131

Poewe, W., see Giladi, N. (4) 741-749

Poisson, A., see Criaud, M. (2) 433-440

Post, B., see Nijhuis, F.A.P. (3) 533-543

Postuma, R.B., see Jacobs, M.L. (1) 231-237

Prokopenko, I., see Lindqvist, D. (1) 99-108

Rabel, C., F.L. Goff, R. Lefaucheur, G. Ozel, D. Fetter, A. Rouillé and D. Maltête, Subjective Perceived Motor Improvement after Acute Levodopa Challenge in Parkinson’s Disease (4) 779-785

Rane, S., see Herb, J.N. (2) 441-451

Ranghetti, A., see Canesi, M. (1) 239-246

Rausch, R., see Paul, K.C. (2) 349-359

Redouté, J., see Criaud, M. (2) 433-440

Reinvang, I., see Hessen, E. (2) 413-421

Ribeiro, J., see Araújo, R. (4) 717-721

Rieu, I., J.L. Houeto, B. Pereira, I. De Chazeron, A. Bichon, I. Chéreau, M. Ulla, C. Brefel-Courbon, F. Ory-Magne, K. Dujardin, F. Tison, P. Krack and F. Durif, Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson’s disease (1) 267-277

Rimmelzwaan, L.M., N.M. van Schoor, P. Lips, H.W. Berendse and E.M.W. Eekhoff, Systematic Review of the Relationship between Vitamin D and Parkinson’s Disease (1) 29-37

Ritz, B., see Paul, K.C. (2) 349-359

Roach, J., see Hacker, M.L. (1) 125-131

Rochester, L., see Hiorth, Y.H. (1) 175-182

Rodríguez-Violante, M., A.J. de Saráchaga, A. Cervantes-Arriaga, R. Millán-Cepeda, R. Leal-Ortega, I. Estrada-Bellmann and C. Zuñiga-Ramírez, Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study (1) 183-190

Rogers, S.L., see Pagan, F. (3) 503-517

Rojas, J.C., see Boman, A. (2) 307-315

Roman, O.C., see Herb, J.N. (2) 441-451

Romenets, S.R., see Jacobs, M.L. (1) 231-237

Rouille, A., see Bouwyn, J.-P. (2) 393-400

Rouillé, A., see Rabel, C. (4) 779-785

Rowse, G.J., see Isaacson, S. (4) 751-759

Rucco, R., see Sorrentino, P. (1) 191-195

Rusconi, M.L., see Canesi, M. (1) 239-246

Sabbagh, M.N., see Beach, T.G. (1) 153-163

Saint-Hilaire, M., see Gunnery, S.D. (3) 625-630

Salkovic, D., see van Uem, J.M.T. (2) 279-287

Sardina, M., see Cattaneo, C. (1) 165-173

Scheller, D., see Stamford, J. (1) 65-66

Schmitt, E., see Lamberti, V.M.J. (1) 133-142

Schulz-Schaeffer, W.J., see Margraf, N.G. (3) 485-501

Scott, S., see Beach, T.G. (1) 153-163

Seeley, W.W., see Boman, A. (2) 307-315

Selnes, P., see Hessen, E. (2) 413-421

Serrano, G., see Beach, T.G. (1) 153-163

Serrano, G., see Beach, T.G. (4) 761-770

Sesar, Á., see Fernández-Pajarín, G. (4) 787-792

Shea, J.A., see Fleisher, J.E. (2) 383-392

Sherer, T.B., see Kurowska, Z. (4) 703-707

Sherer, T.B., see Wyse, R.K. (3) 519-522

Shi, L., see Mak, M.K.Y. (3) 639-650

Shi, M., see Hossein-nezhad, A. (1) 109-117

Shill, H.A., see Beach, T.G. (1) 153-163

Shill, H.A., see Isaacson, S. (4) 751-759

Sibilio, M., see Sorrentino, P. (1) 191-195

Sidtis, D.V.L., see Sidtis, J.J. (2) 361-370

Sidtis, J.J., A.G. Alken, M. Tagliati, R. Alterman and D.V.L. Sidtis, Subthalamic Stimulation Reduces Vowel Space at the Initiation of Sustained Production: Implications for Articulatory Motor Control in Parkinson’s Disease (2) 361-370

Sinsheimer, J.S., see Paul, K.C. (2) 349-359

Sippel, D., see Ossig, C. (3) 597-607

Smith, C.R., see Swallow, D.M.A. (2) 289-300

Sobue, G., see Tanaka, Y. (4) 811-819

Sorrentino, G., see Sorrentino, P. (1) 191-195

Sorrentino, P., A. Barbato, L.D. Gaudio, R. Rucco, P. Varriale, M. Sibilio, P. Strazzullo, G. Sorrentino and V. Agosti, Impaired gait kinematics in type 1 Gaucher’s Disease (1) 191-195

St. Louis, E.K., see Jacobs, M.L. (1) 231-237

Ståhle, A., see Nero, H. (4) 833-840

Stamford, J., D. Scheller and P. Jenner, Parkinson’s Inside Out (1) 65-66

Stav, A.L., see Hessen, E. (2) 413-421

Stenberg, G., Impulse Control Disorders – The Continuum Hypothesis (1) 67-75

Sterling, N.W., M.M. Lewis, G. Du and X. Huang, Structural Imaging and Parkinson’s Disease: Moving Toward Quantitative Markers of Disease Progression (3) 557-567

Sterling, N.W., see He, L. (3) 523-532

Stoessl, A.J., see Kurowska, Z. (4) 703-707

Storch, A., see Ossig, C. (3) 597-607

Strafella, A.P., see Criaud, M. (2) 433-440

Strazzullo, P., see Sorrentino, P. (1) 191-195

Sue, L.I., see Beach, T.G. (1) 153-163

Sue, L.I., see Beach, T.G. (4) 761-770

Sugita, T., see Murakami, H. (1) 209-217

Sumikura, H., see Hatsuta, H. (2) 325-334

Svenningsson, P., see Boman, A. (2) 307-315

Svensson, S., see Boman, A. (2) 307-315

Swallow, D.M.A., M.A. Lawton, K.A. Grosset, N. Malek, C.R. Smith, N.P. Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie, J. Hardy, H.R. Morris, N. Williams, N.W. Wood and D.G. Grosset on behalf of PRoBaND Clinical Consortium, Variation in Recent Onset Parkinson’s Disease: Implications for Prodromal Detection (2) 289-300

Szeto, J.Y.Y., L. Mowszowski, M. Gilat, C.C. Walton, S.L. Naismith and S.J.G. Lewis, Mild Cognitive Impairment in Parkinson’s Disease: Impact on Caregiver Outcomes (3) 589-596

Tábuas-Pereira, M., see Araújo, R. (4) 717-721

Tagliaferro, P. and R.E. Burke, Retrograde Axonal Degeneration in Parkinson Disease (1) 1-5

Tagliati, M., see Sidtis, J.J. (2) 361-370

Takahashi, R., see Izumi, Y. (3) 569-579

Takao, M., see Hatsuta, H. (2) 325-334

Tanaka, Y., T. Tsuboi, H. Watanabe, Y. Kajita, D. Nakatsubo, Y. Fujimoto, R. Ohdake, M. Ito, N. Atsuta, M. Yamamoto, T. Wakabayashi, M. Katsuno and G. Sobue, Articulation Features of Parkinson’s Disease Patients with Subthalamic Nucleus Deep Brain Stimulation (4) 811-819

Teixeira-Pinto, A., see Mendes, A. (4) 793-804

Thobois, S., see Criaud, M. (2) 433-440

Thomas, C.A., see Gunnery, S.D. (3) 625-630

Thomas, M.G., see Johnson, A.R. (3) 609-616

Thompson, L., see Barker, R.A. (1) 57-63

Tickle-Degnen, L., see Gunnery, S.D. (3) 625-630

Tison, F., see Rieu, I. (1) 267-277

Torres-Yaghi, Y., see Pagan, F. (3) 503-517

Trapp, B.D., see Kurowska, Z. (4) 703-707

Tsuboi, T., see Tanaka, Y. (4) 811-819

Tsuda, T., see Hirayama, M. (2) 423-431

Tsunoda, M., see Hirayama, M. (2) 423-431

Turchan, M., see Hacker, M.L. (1) 125-131

Turner, S.D., see Barrett, M.J. (1) 119-124

Tysnes, O.-B., see Hiorth, Y.H. (1) 175-182

Uchino, A., see Hatsuta, H. (2) 325-334

Ulla, M., see Rieu, I. (1) 267-277

Valadez, E.H., see Pagan, F. (3) 503-517

van Dijk, J.G., see Hommel, A.L.A.J. (4) 805-810

van Dijk, J.G., see Molenaar, J.P. (1) 53-55

van Heek, J., see Nijhuis, F.A.P. (3) 533-543

van Schoor, N.M., see Rimmelzwaan, L.M. (1) 29-37

van Uem, J.M.T., T. Isaacs, A. Lewin, E. Bresolin, D. Salkovic, A.J. Espay, H. Matthews and W. Maetzler, A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson’s Disease (2) 279-287

Varriale, P., see Sorrentino, P. (1) 191-195

Venneri, A., see Alzahrani, H. (4) 821-832

Vernino, S., see Isaacson, S. (4) 751-759

Vila-Chã, N., see Mendes, A. (4) 793-804

Wahlestedt, C., see Hossein-nezhad, A. (1) 109-117

Wakabayashi, T., see Tanaka, Y. (4) 811-819

Walker, D.G., see Beach, T.G. (1) 153-163

Walker, J., see Beach, T.G. (4) 761-770

Wallén, M.B., see Nero, H. (4) 833-840

Walton, C.C., see Szeto, J.Y.Y. (3) 589-596

Wang, D., see Mak, M.K.Y. (3) 639-650

Wang, Z.-Y., H. Lian, L. Zhou, Y.-M. Zhang, Q.-Q. Cai, L.-F. Zheng and J.-X. Zhu, Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson’s Disease Rat Model (2) 317-323

Warholak, T., see Bhattacharjee, S. (1) 247-255

Watanabe, H., see Tanaka, Y. (4) 811-819

Weerkamp, N.J., see Hommel, A.L.A.J. (4) 805-810

Weintraub, D., see Fleisher, J.E. (2) 383-392

Weintraut, R., K. Karádi, T. Lucza, M. Kovács, A. Makkos, J. Janszky and N. Kovács, Lille Apathy Rating Scale and MDS-UPDRS for Screening Apathy in Parkinson’s Disease (1) 257-265

Whibley, D., see Barnish, M.S. (3) 453-462

Wilbers, J., see Molenaar, J.P. (1) 53-55

Williams, D.R., see Lee, W. (2) 371-382

Williams, N., see Swallow, D.M.A. (2) 289-300

Wilmarth, B.M., see Pagan, F. (3) 503-517

Woltering, F., see Giladi, N. (4) 741-749

Wong, P.T.-H., see Lee, J.H. (4) 733-739

Wood, N.W., see Swallow, D.M.A. (2) 289-300

Worrall, B.B., see Barrett, M.J. (1) 119-124

Wouters, K., see Martens, H. (1) 219-229

Wouwe, N.V., see Herb, J.N. (2) 441-451

Wrede, A., see Margraf, N.G. (3) 485-501

Wylie, S.A., see Herb, J.N. (2) 441-451

Wyse, R.K., P. Brundin and T.B. Sherer, Nilotinib – Differentiating the Hope from the Hype (3) 519-522

Xia, S., see Gu, Q. (3) 545-556

Xie, S.X., see Fleisher, J.E. (2) 383-392

Xuan, M., see Gu, Q. (3) 545-556

Yamamoto, M., see Hirayama, M. (2) 423-431

Yamamoto, M., see Tanaka, Y. (4) 811-819

Yue, Z., see Kurowska, Z. (4) 703-707

Zabetian, C.P., see Hossein-nezhad, A. (1) 109-117

Zald, D.H., see Herb, J.N. (2) 441-451

Zhang, H., see Gu, Q. (3) 545-556

Zhang, J., see Hossein-nezhad, A. (1) 109-117

Zhang, M., see Gu, Q. (3) 545-556

Zhang, Y.-M., see Wang, Z.-Y. (2) 317-323

Zheng, L.-F., see Wang, Z.-Y. (2) 317-323

Zhou, L., see Wang, Z.-Y. (2) 317-323

Zhu, J.-X., see Wang, Z.-Y. (2) 317-323

Ziemann, A., see Isaacson, S. (4) 751-759

Zuñiga-Ramírez, C., see Rodríguez-Violante, M. (1) 183-190